Merus股票因强劲的二期癌症试验结果飙升超过35%：发生了什么？-动脉网

Merus Stock Surges Over 35% On Strong Phase 2 Cancer Trial Results: What's Going On?

benzinga 等信源发布 2025-05-23 15:18



可切换为仅中文







Merus N.V.

梅鲁斯公司

MRUS

美国俄罗斯

shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab for

周五，该公司报告了其正在进行的 petosemtamab 联合 pembrolizumab 的二期试验中期结果，结果显示股价上涨。

head and neck cancer.

头颈癌。

What To Know:

需要知道的内容：

The data, which will be formally presented at the 2025 ASCO Annual Meeting, showed a 63% overall response rate and a 79% 12-month overall survival rate among 43 evaluable patients with PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma.

数据显示，在43名PD-L1阳性的复发或转移性头颈部鳞状细胞癌患者中，总体缓解率达到63%，12个月的总生存率为79%。该数据将在2025年ASCO年会上正式公布。

The trial also reported a median progression-free survival of nine months, with six patients achieving complete responses and 21 showing partial responses. Importantly, no significant overlapping toxicities were observed in the treatment combination, which was generally well tolerated. Merus noted that 14 responders remained on therapy at the time of the Feb.

试验还报告了中位无进展生存期为九个月，其中六名患者达到完全缓解，21名患者显示部分缓解。重要的是，在这种联合治疗中未观察到显著的重叠毒性，且治疗总体耐受性良好。Merus指出，截至二月，14名有反应的患者仍在接受治疗。

27 2025 data cutoff..

2025年27日数据截止。

Analysts Weigh In:

分析师们的意见：

Needham raised its price target on Merus from $75 to $88, stating the updated data meaningfully de-risk the ongoing phase 3 trials. BMO Capital also raised its target from $96 to $110.

Needham将Merus的目标股价从75美元上调至88美元，称更新的数据显著降低了正在进行的第三阶段试验的风险。BMO资本市场也将其目标股价从96美元上调至110美元。

Topline data from one or both of the ongoing phase 3 studies are expected in 2026.

预计将在2026年获得一个或两个正在进行的三期研究的初步数据。

MRUS Price Action

MRUS价格走势

: Merus shares were up 34.9% at $56.11 at the time of writing, according to

：据数据显示，Merus股价在撰写本文时上涨了34.9%，达到56.11美元。

Benzinga Pro.

Benzinga Pro。

加载中...

Read Next:

接下来读：